Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This article presents the case that a more rapid, individualized approach to treating major depressive disorder (MDD) may increase the likelihood of achieving full symptomatic and functional recovery for individual patients and that studies show it is possible to make earlier decisions about appropriateness of treatment in order to rapidly optimize that treatment. DATA SOURCES: A PubMed search was conducted using terms including major depressive disorder, early improvement, predictor, duration of untreated illness, and function. English-language articles published before September 2015 were included. Additional studies were found within identified research articles and reviews. STUDY SELECTION: Thirty antidepressant studies reporting predictor criteria and outcome measures are included in this review. DATA EXTRACTION: Studies were reviewed to extract definitions of predictors, outcome measures, and results of the predictor analysis. Results were summarized separately for studies reporting effects of early improvement, baseline characteristics, and duration of untreated depression. RESULTS: Shorter duration of the current depressive episode and duration of untreated depression are associated with better symptomatic and functional outcomes in MDD. Early improvement of depressive symptoms predicts positive symptomatic outcomes (response and remission), and early functional improvement predicts an increased likelihood of functional remission. CONCLUSIONS: The approach to treatment of depression that exhibits the greatest potential for achieving full symptomatic and functional recovery is early optimized treatment: early diagnosis followed by rapid individualized treatment. Monitoring symptoms and function early in treatment is crucial to ensuring that patients do not remain on ineffective or poorly tolerated treatment, which may delay recovery and heighten the risk of residual functional deficits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Items 101–118 of 118
Treatment of pharmacoresistant states in psychiatry. Part 2: Treatment-resistant depression
Češková, E. (2025) · Psychiatrie pro praxi · doi:10.36290/psy.2025.015
Gillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Lee, Y., Kim, E. Y., Lee, H. J., Rhee, S. J., Cho, S., Kim, S. H., & Ahn, Y. M. (2022) · Psychiatric Annals · doi:10.3928/00485713-20221110-01
Meisenzahl, E. M., & Wege, N. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23031-8.00010-8
Progress in Biomarkers to Improve Treatment Outcomes in Major Depressive Disorder
Vaccarino, S. R., Ceniti, A. K., Rotzinger, S., & Kennedy, S. H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.024
Self-citationALMEIDA, G. D. S., Barbirato, G. B., Pagnin, V. D. Q., Pagnin, D., & Mesquita, C. T. (2026) · ARQUIVOS BRASILEIROS DE CARDIOLOGIA - IMAGEM CARDIOVASCULAR · doi:10.36660/abcimg.20260048
Kapadia, S., Zhang, Z., Csoboth, C. T., Patel, M., Thase, M. E., & Papakostas, G. I. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf050
Zhu, X., Zhong, R., Chen, X., Feng, L., Feng, Y., Zhang, L., & Wang, G. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.02.001
Carmassi, C., Correll, C. U., de Diego-Adeliño, J., Vian-Lains, A., Oliveira, C., Schneider-Pérez, A., & Sharma, V. M. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01576-6
Christensen, M. C., Ren, H., & Fagiolini, A. (2022) · Figshare · doi:10.6084/m9.figshare.19518603
Yoshioka, K., & Rossetto, A. (2025) · Aging & Mental Health · doi:10.1080/13607863.2025.2519613
Psychologie positive et processus cognitifs dans le traitement de la dépression
Puechbroussou, B. (2024) · theses.fr (ABES) · doi:10.70675/d5b7c126zcc6fz419ez9e9dz64faf24a0880
Yu, J. (n.d.) · PolyU Institutional Research Archive (Hong Kong Polytechnic University)
Jones, A. (2024) · UCL Discovery (University College London)
Takasu, K., Yawata, Y., Tashima, R., Aritomi, H., Shimada, S., Onodera, T., Taishi, T., & Ogawa, K. (2024) · doi:10.3389/fncel.2023.1274459.s006
Yang, L., Su, Y., Dong, S., Wu, T., Zhang, Y., Qiu, H., Gu, W., Qiu, H., Xu, Y., Wang, J., et al. (2022) · doi:10.3389/fphar.2022.954973.s002
Translational Applications of Neuroimaging
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4733-5
Nov antidepresiv, nov način učinkovanja – vortioksetin in njegov način učinkovanja
Terzič, D. (2017) · VICEVERSA
Metadata
- Authors
- Habert, J., Katzman, M. A., Oluboka, O. J., McIntyre, R. S., McIntosh, D., MacQueen, G. M., Khullar, A., Milev, R. V., Kjernisted, K. D., Chokka, P. R., & Kennedy, S. H.
- Affiliations
- University of Toronto (CA)
- START Clinic (CA)
- University of Calgary (CA)
- University of British Columbia (CA)
- University of Alberta (CA)
- Queen's University (CA)
- Corresponding author
- Habert, Jeffrey
- ORCID
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-09-01
- Volume
- 18
- Issue
- 5
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- OpenAlex
- W2513251082
- Cited by
- 84
- References
- 0
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 18 · 2021: 10 · 2020: 5 · 2019: 12 · 2018: 6 · 2017: 3
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, functional recovery, early improvement, depressive episode duration, predictors of treatment response, antidepressant treatment, functional remission, personalized treatment
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Female, Humans, Male, Treatment Outcome, Early Diagnosis, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.